Show simple item record

dc.contributor.advisorBerkland, Cory
dc.contributor.authorKuehl, Christopher
dc.date.accessioned2016-10-11T19:15:18Z
dc.date.available2016-10-11T19:15:18Z
dc.date.issued2015-12-31
dc.date.submitted2015
dc.identifier.otherhttp://dissertations.umi.com/ku:14279
dc.identifier.urihttp://hdl.handle.net/1808/21663
dc.description.abstractPulmonary drug delivery has been an underutilized delivery space. Classically, pulmonary delivery has been employed for local delivery of small molecules for lung-centric respiratory diseases. The most typical example has been the application of corticosteroids as a treatment for asthma. There are multiple issues with this approach primarily focused on delivery as current formulations do not achieve a high amount of deposition into the lungs, which is countered by increased dose. To counter this, particle engineering strategies have been employed to improve delivery. By engineering our nanoparticle agglomerates, called NanoClusters, we have achieved increased deposition into the lungs. Corticosteroids are poorly water soluble and as such, dissolve slowly. There are lung clearance mechanisms that can clear these engineered NanoClusters before they dissolve, so the dissolution was assessed. It was observed that NanoClusters had enhanced dissolution making them an optimal system for lung delivery. The lungs can be employed for regional and systemic delivery and not just local. The next study focused on delivery of a polymer, hyaluronic acid (HA) into the lungs. HA of different molecular weights was labeled, either fluorescently or with a radiolabel, and administered to mice. Labeled HA was tracked throughout the organs to determine the biodistribution of the polymer according to molecular weight along with determination of the pharmacokinetic parameters. The optimal size was determined to be between 67 and 215 kDa for HA to achieve increased persistence in the lungs. The lungs can be involved in the immune system as well in terms of systemic delivery. Recent research has shown that the lungs may contribute to profile switching in immune cells leading to different responses. By employing antigen presentation in a soluble antigen array for autoimmune diseases, there can be increased efficacy towards generating immune tolerance. By co-delivering two different antigens to the lungs, there is amelioration of the mouse model of multiple sclerosis suggesting the lungs may be a delivery space with increased possibilities in the future.
dc.format.extent161 pages
dc.language.isoen
dc.publisherUniversity of Kansas
dc.rightsCopyright held by the author.
dc.subjectPharmaceutical sciences
dc.subjectDry Powder Aerosols
dc.subjectHyaluronic Acid
dc.subjectImmune Modulation
dc.subjectParticle Engineering
dc.subjectPulmonary Drug Delivery
dc.titleEngineering Particles and Polymers to Improve Pulmonary Therapeutics
dc.typeDissertation
dc.contributor.cmtememberBerkland, Cory
dc.contributor.cmtememberForrest, Laird
dc.contributor.cmtememberStobaugh, John
dc.contributor.cmtememberWang, Michael
dc.contributor.cmtememberPrisinzano, Tom
dc.thesis.degreeDisciplinePharmaceutical Chemistry
dc.thesis.degreeLevelPh.D.
dc.provenance04/05/2017: The ETD release form is attached to this record as a license file.
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record